Epilepsy, which affects around 3 million people in the U.S., is a condition that causes seizures in the patients, sometimes with life-threatening consequences. People who experience epilepsy seizures require medicines, remedies, and treatments to ensure that the condition does not paralyze or incapacitate them. Epilepsy can be dealt with confidently with the help of medicines, remedies, and proper treatments such that the patients do not suffer from regular seizures and live a normal life. In the last decade, many medicines have been researched, tested, and approved as the treatments. Remedies for treatments of epilepsy and preventing seizures or the medicines given to the affected person: Though there are many medicines that could be prescribed as treatments for epilepsy and to prevent seizures, finding the right medicine and determining the dosage is crucial. Epilepsy medicines and treatments cause side effects; therefore the purpose of novel remedies and treatments is to ensure that there are no seizures and no side effects. Nerve Stimulation as One of the Remedies for Epilepsy Nerve stimulation has been known to be effective as one of the better remedies and treatments prescribed to control seizures. Implantable nerve stimulation devices such as a vagus nerve stimulator (VNS) can … Continue reading →

Early resubmission opportunity for epilepsy drug perampanel welcomed by Eisai The German Federal Joint Committee (G-BA), the decision-making body of the self-governing healthcare system in Germany, recently confirmed that Eisai will be able to resubmit early its anti-epileptic drug (AED) Fycompa (perampanel) for reassessment of its additional therapeutic benefits. Perampanel is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.[1] The confirmation from the G-BA gives Eisai the right to resubmit perampanel for additional benefit reassessment within three months now. Once resubmitted, the new G-BA decision is expected to be published within 6 months. "It is right that the G-BA has permitted the early resubmission of Fycompa in Germany," said Gary Hendler, President & CEO, Eisai EMEA. "Patients are Eisai's first concern and we strongly believe they should be given access to treatment that provides a clear clinical benefit. Since the launch of Fycompa across Europe in September 2012, its clinical benefit has been recognised in approximately 4,000 people with epilepsy in Germany and we hope it will be available to many more in the near future." Eisai temporarily suspended perampanel from distribution in Germany … Continue reading →

PUBLIC RELEASE DATE: 9-Feb-2014 Contact: News & Information Office press.office@admin.ox.ac.uk 44-018-652-80530 University of Oxford Seven new genetic regions associated with type 2 diabetes have been identified in the largest study to date of the genetic basis of the disease. DNA data was brought together from more than 48,000 patients and 139,000 healthy controls from four different ethnic groups. The research was conducted by an international consortium of investigators from 20 countries on four continents, co-led by investigators from Oxford University's Wellcome Trust Centre for Human Genetics. The majority of such 'genome-wide association studies' have been done in populations with European backgrounds. This research is notable for including DNA data from populations of Asian and Hispanic origin as well. The researchers believe that, as more genetic data increasingly become available from populations of South Asian ancestry and, particularly, African descent, it will be possible to map genes implicated in type 2 diabetes ever more closely. 'One of the striking features of these data is how much of the genetic variation that influences diabetes is shared between major ethnic groups,' says Wellcome Trust Senior Investigator Professor Mark McCarthy from the University of Oxford. 'This has allowed us to combine data from more … Continue reading →